Prognostic value of CT coronary angiography: focus on obstructive vs. nonobstructive disease and on the presence of left main disease.
E Maffei, S Seitun, C Martini...
https://pubmed.ncbi.nlm.nih.gov/20927651/Actively Recruiting
Led by Azienda Ospedaliero-Universitaria di Parma · Updated on 2021-01-13
1000
Participants Needed
11
Research Sites
313 weeks
Total Duration
This research aims to gather a large group of patients suspected of having coronary artery disease CAD who underwent Computed Tomography Coronary Angiography CTCA to better understand how CTCA helps in identifying the presence and severity of CAD and predicting patient outcomes. The study focuses on assessing the added value of CTCA to current methods in determining disease burden and cardiovascular risk. It is an observational retrospective study analyzing data collected from patients evaluated with CTCA over the past several years. Patients included in the study had CTCA performed using at least 64-slice CT technology or 16-slice with more than 4 years follow-up and had a calcium score available. The study collects data retrospectively from institutional databases, including clinical history, CTCA results, and follow-up records. Patients were classified based on CTCA findings into groups with normal arteries, non-obstructive CAD, or obstructive CAD. Data include detailed CT scanning protocols and administration of medications like beta-blockers and nitroglycerine during imaging. Participants information, such as cardiovascular risk factors and symptoms, was collected from clinical databases and interviews. Outcomes tracked include major adverse cardiovascular events MACE, coronary revascularizations, and shifts in cardiovascular risk categories. Follow-up data were obtained through outpatient visits, phone contacts, and medical records review, with a minimum follow-up of 6 to 12 months. Researchers analyze outcomes using various statistical methods to identify predictors of risk and the incremental value of CTCA in prognosis.
CONDITIONS
Computed Tomography Coronary Angiography (CTCA) Prognostic Registry for Coronary Artery Disease
F
Filippo Cademartiri, MD, PhD
E
Erica Maffei, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Ospedaliero-Universitaria di Parma
Lead Sponsor
Società Italiana di Radiologia Medica
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day procedure
Participants undergo Computed Tomography Coronary Angiography (CTCA) and Coronary Artery Calcium Score assessment to evaluate coronary artery disease and cardiovascular risk.
1 visit (in-person)
Duration - At least 12 months
Participants are followed for clinical outcomes including major adverse cardiovascular events and coronary revascularizations through outpatient visits, phone contacts, or data collection from clinical databases.
Follow-up visits and/or phone contacts as needed during the follow-up period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
E Maffei, S Seitun, C Martini...
https://pubmed.ncbi.nlm.nih.gov/20927651/E Maffei, S Seitun, C Martini...
https://pubmed.ncbi.nlm.nih.gov/21424322/E Maffei, M Midiri, V Russo...
https://pubmed.ncbi.nlm.nih.gov/23358817/Annachiara Aldrovandi, Erica Maffei, Alessandro Palumbo...
https://pubmed.ncbi.nlm.nih.gov/19224218/Jacob M Van Werkhoven, Filippo Cademartiri, Sara Seitun...
https://pubmed.ncbi.nlm.nih.gov/20574086/Annachiara Aldrovandi, Erica Maffei, Sara Seitun...
https://pubmed.ncbi.nlm.nih.gov/21052023/Azienda Ospedaliero-Universitaria di Parma
Lead Sponsor
Società Italiana di Radiologia Medica
Collaborating Sponsor